本研究是一项双盲、安慰剂对照的随机临床试验,旨在评估Pitavastatin对非钙化冠状动脉斑块的影响及其作为MACE预防的潜在机制。研究从2015年4月至2018年2月在美国31个临床研究中心招募了参与者,包括正在接受抗反转录病毒治疗且10年内CVD风险低至中等...
In short-term, phase III or IV studies in this patient population, pitavastatin 1–4 mg once daily was generally no less effective than presumed equipotent dosages of atorvastatin and simvastatin (including in patients with type 2 diabetes or ≥2 cardiovascular risk factors) and was ...
pitavastatin null 2 mg 通用名称 pitavastatin 中文名称 匹伐他汀 剂型 Film-coated tablet MR编号 PT/H/2682/002 申请类型1 Prescription Only 申请类型2 Initial Application 申请类型3 Generic Art 10.1 and 10.2 Dir 2001/83/EC 申请类型4 Chemical Substance ...
Incidence of NOD was similar between the pitavastatin 1 mg and 4 mg groups [12 of 289 patients (4.2%) and 8 of 289 patients (2.8%), respectively; p = 0.36]. In a prespecified analysis, there were no significant differences in NOD events according to sex, age, diagnosis, body ...
A pharmacokinetics study was conducted in 12 Chinese volunteers following a single dose of 1 mg, 2 mg and 4 mg of pitavastatin calcium in an open-label, randomized, three-period crossover design. Plasma concentrations of pitavastatin acid and pitavastatin lactone were determined by a HPLC method...
Patients received pitavastatin 2 mg once daily or simvastatin 20 mg once daily for 8weeks. The medication was administered initially for 4 weeks, and an additional 4 weeks of study medication was prescribed at week 4. The final visit was conducted 8 weeks after randomization. Results: Of the ...
PitavastatinStudy protocol. A total of 1044 patients underwent randomization in a 1:1 ratio to receive lowest dose (1mg) or highest dose pitavastatin (4mg) therapy for 3years. After propensity score matching, 289 patients were enrolled in each group...
(by the pooled cohort equations from the American College of Cardiology and American Heart Association) without DM at study entry.Intervention:Random 1:1 assignment to pitavastatin, 4 mg daily, or placebo.Measurements:New-onset DM was determined at each visit by clinical diagnosis requiring ...
Current guidelines recommend LDLc levels below 100mg/dL in patients with established CVD and less than 70-80mg/dL in very high risk patients. In patients at LDLc target, the risk of major cardiovascular events is only reduced about one third, remaining an important residual risk, due in part...
Eligible patients were those who had both stable coronary artery disease and hypercholesterolemia of low-density lipoprotein cholesterol (LDL-C) >100 mg/dL and started to take treatment (pitavastatin, 4 mg/day). Pre-and post-treatment complete blood count values and lipid...